Daiichi Sankyo, Ranbaxy To Launch Olmesartan In Six African Countries
This article was originally published in PharmAsia News
Executive Summary
TOKYO - In what is being called the first formidable entry into the African market by a leading pharmaceutical group, Daiichi Sankyo and its Indian generic subsidiary Ranbaxy announced Dec. 22 they will jointly launch Daiichi's proprietary hypertension treatment Olvance (olmesartan) in the six countries of Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia
You may also be interested in...
Daiichi Sankyo Acquires U.S. Generic Injectables Maker PharmaForce
TOKYO - Daiichi Sankyo's U.S. subsidiary, Luitpold Pharmaceutical of New York has fully acquired PharmaForce of Columbus, Ohio, a specialty injectable pharmaceutical company, the Tokyo-based company said
Daiichi Sankyo Acquires U.S. Generic Injectables Maker PharmaForce
TOKYO - Daiichi Sankyo's U.S. subsidiary, Luitpold Pharmaceutical of New York has fully acquired PharmaForce of Columbus, Ohio, a specialty injectable pharmaceutical company, the Tokyo-based company said
Daiichi Sankyo, Ranbaxy To Start Joint Marketing In Mexico, Romania
TOKYO - Dust from their merger settled, Daiichi Sankyo and generics manufacturing Indian subsidiary Ranbaxy are flexing their muscles, readying to start marketing brand and generic pharmaceuticals in Mexico and launching the postmenopausal osteoporosis drug Evista in Romania